Mean platelet volume may not be a significant prognostic factor in patients with metastatic castration-resistant prostate cancer

被引：0
|
作者：
Cengiz Beyan
Esin Beyan
机构：
[1] Ufuk University Faculty of Medicine,Department of Internal Medicine
[2] University of Health Sciences,undefined
[3] Kecioren Training and Research Hospital,undefined
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Drug therapy; Mean platelet volume; Predictive value of tests; Prognosis; Prostatic neoplasms;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2175 / 2176
页数：1
相关论文
共 50 条
  • [31] Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel
    Yokom, Daniel W.
    Stewart, John
    Alimohamed, Nimira S.
    Winquist, Eric
    Berry, Scott
    Hubay, Stacey
    Lattouf, Jean-Baptiste
    Leonard, Helene
    Girolametto, Carla
    Saad, Fred
    Sridhar, Srikala S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2018, 12 (08): : E365 - E372
  • [32] Inflammatory factor-based prognostic risk stratification for patients with metastatic castration-resistant prostate cancer treated with docetaxel
    Shi, Xinyu
    Fan, Junjie
    Pei, Xinqi
    Wang, Yuzhao
    Guo, Guodong
    Yang, Tao
    Wang, Xinyang
    He, Dalin
    Li, Lei
    ANDROLOGIA, 2021, 53 (06)
  • [33] Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
    Belderbos, Bodine P. S.
    de Wit, Ronald
    Oomen-de Hoop, Esther
    Nieuweboer, Annemieke
    Hamberg, Paul
    van Alphen, Robbert J.
    Bergman, Andre
    van der Meer, Nelly
    Bins, Sander
    Mathijssen, Ron H. J.
    van Soest, Robert J.
    ONCOTARGET, 2017, 8 (63) : 106468 - 106474
  • [34] LONGITUDINAL PAIN SCORES AS A PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Wang, Wei
    Kwon, Young Suk
    Su, Lixiao
    Kim, Isaac Yi
    Lu, Shou-En
    JOURNAL OF UROLOGY, 2017, 197 (04): : E765 - E765
  • [35] Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer
    De Laere, Bram
    Crippa, Alessio
    Mortezavi, Ashkan
    Ghysel, Christophe
    Rajan, Prabhakar
    Eklund, Martin
    Wyatt, Alexander
    Dirix, Luc
    Ost, Piet
    Gronberg, Henrik
    Lindberg, Johan
    CANCERS, 2021, 13 (07)
  • [36] Treatment strategies in low-volume metastatic castration-resistant prostate cancer
    Wei, Xiao X.
    Ko, Eric C.
    Ryan, Charles J.
    CURRENT OPINION IN UROLOGY, 2017, 27 (06) : 596 - 603
  • [37] Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
    Lin, Ting-Ting
    Chen, Ye-Hui
    Wu, Yu-Peng
    Chen, Shao-Zhan
    Li, Xiao-Dong
    Lin, Yun-Zhi
    Chen, Shao-Hao
    Zheng, Qing-Shui
    Wei, Yong
    Xu, Ning
    Xue, Xue-Yi
    JOURNAL OF CANCER, 2019, 10 (22): : 5608 - 5613
  • [38] Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy
    Linton, Anthony
    Pond, Greg
    Clarke, Stephen
    Vardy, Janette
    Galsky, Matthew
    Sonpavde, Guru
    CLINICAL GENITOURINARY CANCER, 2013, 11 (04) : 423 - 430
  • [39] Prostate-specific antigen doubling time in metastatic castration-resistant prostate cancer: a clinically useful prognostic factor
    Colloca, G.
    Guarneri, D.
    Addamo, G.
    Venturino, A.
    Coccorullo, Z.
    Ratti, R.
    Campora, E.
    EJC SUPPLEMENTS, 2009, 7 (04): : 14 - 14
  • [40] Circulating tumor cells in patients with castration-resistant metastatic prostate cancer
    Danila, D. C.
    Leversha, M. A.
    Gonzalez-Espinoza, R.
    Anand, A.
    Gu, B.
    Gignac, G. A.
    Larson, S.
    Heller, G.
    Fleisher, M.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345